Get the Stockscreener App
1.63
1.87%
0.03
Sab Biotherapeutics Inc Stock (SABS) Forecast
The Sab Biotherapeutics Inc (SABS) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $2.6374, representing a +61.81% increase from the current price of $1.63. The highest analyst price target is $2.7703, and the lowest is $2.5046.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month SABS Price Target
Average 2.3805
(+46.04% Upside)
Is Sab Biotherapeutics Inc (SABS) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 38.93 | Neutral |
| STOCH(9,6) | 34.12 | Neutral |
| STOCHRSI(14) | 100.00 | Sell |
| MACD(12,26) | -0.2406 | Buy |
| ADX(14) | 23.32 | Neutral |
| William %R | -59.69 | Neutral |
| CCI(14) | -3.8692 | Neutral |
Buy: 1
Sell: 1
Neutral: 5
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
1.609
Buy
|
1.6318
Sell
|
| MA20 |
1.7222
Sell
|
1.7774
Sell
|
| MA50 |
2.5338
Sell
|
2.2896
Sell
|
| MA100 |
2.9769
Sell
|
2.6929
Sell
|
| MA200 |
2.881
Sell
|
3.4263
Sell
|
Buy: 1
Sell: 9
Neutral: 0
Summary: Sell
According to our latest analysis, SABS could be considered a Strong Sell, with 17 technical analysis indicators signaling 2 Buy signals, 10 signaling Sell signals and 5 Neutral signals. This might not be a good time to consider opening new positions on SABS, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 38.93 indicates that SABS is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 34.12 indicates that SABS is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 100 indicates that SABS is oversold. This suggests that SABS price is at or near the highest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 23.32 suggests that there may be some movement in price, but it lacks strength or conviction.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -3.8692 indicates that SABS is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.
Long-term SABS price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Sab Biotherapeutics Inc financial reports and earnings history, Sab Biotherapeutics Inc (SABS) stock could reach $0.6562 by 2030, $18.80 by 2040 and $15.60 by 2050. See the projected annual prices until 2050 of the Sab Biotherapeutics Inc stock below:
- Sab Biotherapeutics Inc (SABS) is expected to reach an average price of $10.03 in 2035, with a high prediction of $10.05 and a low estimate of $10.01. This indicates an $515.15% rise from the last recorded price of $1.63.
- Sab Biotherapeutics Inc (SABS) stock is projected to chart a bullish course in 2040, with an average price target of $18.79, representing an $1,053% surge from its current level. The forecast ranges from a conservative $18.81 to a sky-high $18.80.
- Our analysts predict Sab Biotherapeutics Inc (SABS) to jump 1,640% by 2045, soaring from $28.22 to an average price of $28.37, potentially reaching $27.96. While $28.22 is the low estimate, the potential upside is significant.
- Sab Biotherapeutics Inc (SABS) stock is expected to climb by 2050, reaching an average of $14.91, a $814.99% jump from its current level. However, a wide range of estimates exists, with high and low targets of $15.60 and $14.80, respectively, highlighting the market's uncertainty.
Sab Biotherapeutics Inc Stock (SABS) Year by Year Forecast
Sab Biotherapeutics Inc Stock (SABS) Price Forecast for 2025
Sab Biotherapeutics Inc Stock (SABS) is expected to reach an average price of $2.3159 in 2025, with a high prediction of $2.7703 and a low estimate of $1.8614. This indicates an +42.08% rise from the last recorded price of $1.63.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| April, 2025 | $2.827 | $2.5046 | $2.7703 | +73.44% |
| May, 2025 | $2.4696 | $2.7396 | $2.6117 | +51.51% |
| June, 2025 | $2.4921 | $2.5421 | $2.5168 | +52.89% |
| July, 2025 | $2.2403 | $2.2902 | $2.2678 | +37.44% |
| August, 2025 | $2.5728 | $2.2659 | $2.3128 | +57.84% |
| September, 2025 | $2.4753 | $2.55 | $2.5585 | +51.86% |
| October, 2025 | $2.4403 | $2.4725 | $2.4309 | +49.71% |
| November, 2025 | $2.5192 | $2.4504 | $2.4147 | +54.55% |
| December, 2025 | $2.2786 | $2.5516 | $2.5358 | +39.79% |
Sab Biotherapeutics Inc Stock (SABS) Price Forecast for 2026
The predicted value for Sab Biotherapeutics Inc (SABS) in 2026 is set at an average of $3.0814. Estimates vary from a peak of $4.6128 to a trough of $1.5499, indicating an +89.04% surge from the present price of $1.63.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $2.0202 | $2.0966 | $1.9954 | +23.94% |
| February, 2026 | $1.9726 | $2.0092 | $2.0023 | +21.02% |
| March, 2026 | $2.0017 | $1.9907 | $1.9917 | +22.80% |
| April, 2026 | $1.9498 | $1.9486 | $1.9573 | +19.62% |
| May, 2026 | $2.0323 | $1.965 | $1.9111 | +24.68% |
| June, 2026 | $1.9949 | $1.9844 | $1.9749 | +22.38% |
| July, 2026 | $1.614 | $1.9325 | $2.0195 | -0.98% |
| August, 2026 | $1.5452 | $1.5499 | $1.5686 | -5.20% |
| September, 2026 | $1.6032 | $1.5576 | $1.5313 | -1.65% |
| October, 2026 | $3.4338 | $1.6909 | $4.6128 | +110.66% |
| November, 2026 | $3.6713 | $2.4713 | $4.0182 | +125.23% |
| December, 2026 | $2.2031 | $1.9631 | $3.7644 | +35.16% |
Sab Biotherapeutics Inc Stock (SABS) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Sab Biotherapeutics Inc (SABS) is $2.9346, with a high forecast of $5.8691 and a low forecast of $0.000071. This indicates an +80.04% increase from the last price of $1.63.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $2.6806 | $1.7719 | $4.0863 | +64.46% |
| February, 2027 | $2.1481 | $1.815 | $2.7981 | +31.79% |
| March, 2027 | $0.7887 | $0.4013 | $2.5225 | -51.61% |
| April, 2027 | $1.5437 | $0.0938 | $3.7537 | -5.29% |
| May, 2027 | $0.4113 | $0.000071 | $1.9512 | -74.77% |
| June, 2027 | $2.2676 | $0.8726 | $2.2176 | +39.12% |
| July, 2027 | $2.9927 | $2.9489 | $2.6627 | +83.60% |
| August, 2027 | $5.8477 | $3.0339 | $5.8377 | +258.75% |
| September, 2027 | $4.824 | $4.5115 | $5.599 | +195.95% |
| October, 2027 | $5.599 | $5.2252 | $5.194 | +243.50% |
| November, 2027 | $5.3441 | $5.6066 | $5.4729 | +227.86% |
| December, 2027 | $5.9404 | $5.9404 | $5.8691 | +264.44% |
Sab Biotherapeutics Inc Stock (SABS) Price Forecast for 2028
In 2028, Sab Biotherapeutics Inc (SABS) is projected to reach an average price of $5.6607, with a high projection of $6.2865 and a low estimate of $5.0349. This indicates an +247.28% rise from the last price of $1.63.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $6.1354 | $6.0541 | $6.0029 | +276.40% |
| February, 2028 | $6.2214 | $6.0692 | $6.0204 | +281.68% |
| March, 2028 | $6.2768 | $6.3167 | $6.2865 | +285.08% |
| April, 2028 | $6.0818 | $6.0895 | $6.0681 | +273.11% |
| May, 2028 | $5.498 | $5.6853 | $5.9233 | +237.30% |
| June, 2028 | $5.6221 | $5.5718 | $5.5006 | +244.91% |
| July, 2028 | $5.8581 | $5.75 | $5.807 | +259.39% |
| August, 2028 | $5.634 | $5.6543 | $5.6219 | +245.64% |
| September, 2028 | $5.5594 | $5.5794 | $5.5457 | +241.07% |
| October, 2028 | $5.5966 | $5.5407 | $5.5232 | +243.35% |
| November, 2028 | $5.0525 | $5.3008 | $5.5686 | +209.97% |
| December, 2028 | $4.9558 | $5.0349 | $4.9346 | +204.04% |
Sab Biotherapeutics Inc Stock (SABS) Price Forecast for 2029
The 2029 price forecast for Sab Biotherapeutics Inc Stock (SABS) is $2.4811 on average, with a high prediction of $4.8772 and a low estimate of $0.085. This represents an +52.21% increase from the previous price of $1.63.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $4.8821 | $4.8655 | $4.8772 | +199.52% |
| February, 2029 | $4.7271 | $4.7371 | $4.8234 | +190.01% |
| March, 2029 | $4.6929 | $4.7104 | $4.6816 | +187.91% |
| April, 2029 | $4.6138 | $4.658 | $4.621 | +183.06% |
| May, 2029 | $4.5435 | $4.6155 | $4.65 | +178.74% |
| June, 2029 | $4.0886 | $4.1204 | $4.4248 | +150.84% |
| July, 2029 | $4.0736 | $4.0798 | $4.0598 | +149.91% |
| August, 2029 | $4.1289 | $4.0157 | $4.0346 | +153.31% |
| September, 2029 | $1.2851 | $0.5851 | $4.049 | -21.16% |
| October, 2029 | $0.9188 | $0.1426 | $1.4788 | -43.63% |
| November, 2029 | $0.9038 | $0.085 | $0.9574 | -44.55% |
| December, 2029 | $0.00127 | $0.0913 | $1.8725 | -99.92% |
Sab Biotherapeutics Inc Stock (SABS) Price Forecast for 2030
Sab Biotherapeutics Inc Stock (SABS) is expected to reach an average price of $4.8839 in 2030, with a high forecast of $9.7615 and a low forecast of $0.00621. This signifies an +199.62% surge from the last price of $1.63.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $0.3312 | $0.00621 | $0.6562 | -79.68% |
| February, 2030 | $2.0907 | $3.3838 | $4.03 | +28.26% |
| March, 2030 | $3.6382 | $2.8276 | $2.2613 | +123.20% |
| April, 2030 | $5.4958 | $4.1251 | $4.3758 | +237.16% |
| May, 2030 | $6.4102 | $6.7927 | $6.2564 | +293.26% |
| June, 2030 | $9.3378 | $7.0009 | $6.9478 | +472.87% |
| July, 2030 | $8.1822 | $8.3922 | $9.7615 | +401.98% |
| August, 2030 | $8.9698 | $9.0629 | $8.616 | +450.29% |
| September, 2030 | $9.3173 | $9.1766 | $9.1961 | +471.61% |
| October, 2030 | $9.5818 | $9.3436 | $9.4519 | +487.84% |
| November, 2030 | $9.7393 | $9.6055 | $9.6393 | +497.50% |
| December, 2030 | $9.6169 | $9.6762 | $9.6062 | +489.99% |
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):